Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Net Cash Flow (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Cash Flow for 14 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 116.31% year-over-year to -$2.6 million; the TTM value through Dec 2025 reached -$15.0 million, down 52.63%, while the annual FY2025 figure was -$17.6 million, 3377.24% down from the prior year.
  • Net Cash Flow hit -$2.6 million in Q4 2025 for Traws Pharma, up from -$4.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $29.0 million in Q1 2021 and bottomed at -$11.5 million in Q3 2024.
  • Average Net Cash Flow over 5 years is -$1.1 million, with a median of -$4.3 million recorded in 2021.
  • Year-over-year, Net Cash Flow soared 614.84% in 2021 and then plummeted 156.79% in 2024.
  • Traws Pharma's Net Cash Flow stood at -$4.3 million in 2021, then grew by 9.67% to -$3.9 million in 2022, then decreased by 14.06% to -$4.4 million in 2023, then skyrocketed by 459.75% to $15.9 million in 2024, then crashed by 116.31% to -$2.6 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$2.6 million, -$4.1 million, and -$2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.